105 related articles for article (PubMed ID: 34352652)
1. Spatial-Frequency dual-branch attention model for determining KRAS mutation status in colorectal cancer with T2-weighted MRI.
Ma Y; Wang J; Song K; Qiang Y; Jiao X; Zhao J
Comput Methods Programs Biomed; 2021 Sep; 209():106311. PubMed ID: 34352652
[TBL] [Abstract][Full Text] [Related]
2. SG-Transunet: A segmentation-guided Transformer U-Net model for KRAS gene mutation status identification in colorectal cancer.
Ma Y; Guo Y; Cui W; Liu J; Li Y; Wang Y; Qiang Y
Comput Biol Med; 2024 May; 173():108293. PubMed ID: 38574528
[TBL] [Abstract][Full Text] [Related]
3. A multitask dual-stream attention network for the identification of KRAS mutation in colorectal cancer.
Song K; Zhao Z; Ma Y; Wang J; Wu W; Qiang Y; Zhao J; Chaudhary S
Med Phys; 2022 Jan; 49(1):254-270. PubMed ID: 34806195
[TBL] [Abstract][Full Text] [Related]
4. FDTrans: Frequency Domain Transformer Model for predicting subtypes of lung cancer using multimodal data.
Cai M; Zhao L; Hou G; Zhang Y; Wu W; Jia L; Zhao J; Wang L; Qiang Y
Comput Biol Med; 2023 May; 158():106812. PubMed ID: 37004434
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive KRAS mutation estimation in colorectal cancer using a deep learning method based on CT imaging.
He K; Liu X; Li M; Li X; Yang H; Zhang H
BMC Med Imaging; 2020 Jun; 20(1):59. PubMed ID: 32487083
[TBL] [Abstract][Full Text] [Related]
6. CT texture analysis for the prediction of KRAS mutation status in colorectal cancer via a machine learning approach.
Taguchi N; Oda S; Yokota Y; Yamamura S; Imuta M; Tsuchigame T; Nagayama Y; Kidoh M; Nakaura T; Shiraishi S; Funama Y; Shinriki S; Miyamoto Y; Baba H; Yamashita Y
Eur J Radiol; 2019 Sep; 118():38-43. PubMed ID: 31439256
[TBL] [Abstract][Full Text] [Related]
7. Relationship between KRAS mutations and dual time point
Mao W; Zhou J; Zhang H; Qiu L; Tan H; Hu Y; Shi H
Abdom Radiol (NY); 2019 Jun; 44(6):2059-2066. PubMed ID: 30143816
[TBL] [Abstract][Full Text] [Related]
8. Relationship between KRAS mutation and diffusion weighted imaging in colorectal liver metastases; Preliminary study.
Gültekin MA; Türk HM; Beşiroğlu M; Toprak H; Yurtsever I; Yilmaz TF; Sharifov R; Uysal Ö
Eur J Radiol; 2020 Apr; 125():108895. PubMed ID: 32109834
[TBL] [Abstract][Full Text] [Related]
9. Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?
Yang L; Dong D; Fang M; Zhu Y; Zang Y; Liu Z; Zhang H; Ying J; Zhao X; Tian J
Eur Radiol; 2018 May; 28(5):2058-2067. PubMed ID: 29335867
[TBL] [Abstract][Full Text] [Related]
10. A rational two-step approach to KRAS mutation testing in colorectal cancer using high resolution melting analysis and pyrosequencing.
Mack E; Stabla K; Riera-Knorrenschild J; Moll R; Neubauer A; Brendel C
BMC Cancer; 2016 Aug; 16():585. PubMed ID: 27485514
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
[TBL] [Abstract][Full Text] [Related]
12. Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms.
Shiri I; Maleki H; Hajianfar G; Abdollahi H; Ashrafinia S; Hatt M; Zaidi H; Oveisi M; Rahmim A
Mol Imaging Biol; 2020 Aug; 22(4):1132-1148. PubMed ID: 32185618
[TBL] [Abstract][Full Text] [Related]
13. Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to KRAS Mutation Status.
Inamura K; Song M; Jung S; Nishihara R; Yamauchi M; Lochhead P; Qian ZR; Kim SA; Mima K; Sukawa Y; Masuda A; Imamura Y; Zhang X; Pollak MN; Mantzoros CS; Harris CC; Giovannucci E; Fuchs CS; Cho E; Chan AT; Wu K; Ogino S
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26598515
[TBL] [Abstract][Full Text] [Related]
14. The value of
Oner AO; Budak ES; Yıldırım S; Aydın F; Sezer C
Hell J Nucl Med; 2017; 20(2):160-165. PubMed ID: 28697193
[TBL] [Abstract][Full Text] [Related]
15. Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.
Jiang L; Huang J; Morehouse C; Zhu W; Korolevich S; Sui D; Ge X; Lehmann K; Liu Z; Kiefer C; Czapiga M; Su X; Brohawn P; Gu Y; Higgs BW; Yao Y
Cancer Genet; 2013; 206(9-10):330-9. PubMed ID: 24200637
[TBL] [Abstract][Full Text] [Related]
16. ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.
Segelov E; Waring P; Desai J; Wilson K; Gebski V; Thavaneswaran S; Elez E; Underhill C; Pavlakis N; Chantrill L; Nott L; Jefford M; Khasraw M; Day F; Wasan H; Ciardiello F; Karapetis C; Joubert W; van Hazel G; Haydon A; Price T; Tejpar S; Tebbutt N; Shapiro J
BMC Cancer; 2016 May; 16():339. PubMed ID: 27246726
[TBL] [Abstract][Full Text] [Related]
17. Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review.
Han van Krieken J; Kafatos G; Bennett J; Mineur L; Tomášek J; Rouleau E; Fabian P; De Maglio G; García-Alfonso P; Aprile G; Parkar P; Downey G; Demonty G; Trojan J
BMC Cancer; 2017 Nov; 17(1):798. PubMed ID: 29183279
[TBL] [Abstract][Full Text] [Related]
18. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of KRAS mutational status on long-term survival according to the timing of colorectal liver metastases.
Sakai N; Furukawa K; Takayashiki T; Kuboki S; Takano S; Ohtsuka M
BMC Cancer; 2021 Apr; 21(1):412. PubMed ID: 33858364
[TBL] [Abstract][Full Text] [Related]
20. RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014.
Lièvre A; Merlin JL; Sabourin JC; Artru P; Tong S; Libert L; Audhuy F; Gicquel C; Moureau-Zabotto L; Ossendza RA; Laurent-Puig P; Ducreux M
Dig Liver Dis; 2018 May; 50(5):507-512. PubMed ID: 29396127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
